On November 24, 2020 The Board of Directors of Scandion Oncology A/S ("Scandion Oncology" or the "Company") reported that it has prepared a prospectus (the "Prospectus") relating to the issue of new shares with preferential rights for existing shareholders of approximately SEK 236 million (the "Rights Issue"), which was resolved on by the Board of Directors on 16 November 2020, pursuant to the authorization granted by the extraordinary general meeting held on 13 November 2020 (Press release, Scandion Oncology, NOV 24, 2020, View Source,c3242441 [SID1234574541]). The Prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). Today, the Company also announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Not for publication, distribution or announcement, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or any other jurisdiction in which publication, distribution or announcement of this press release is unlawful or is subject to legal restrictions other than those required by Swedish law.

Publication of Prospectus

The Prospectus has been prepared relating to the Rights Issue and has today, 24 November 2020, been approved by and registered with the Swedish Financial Supervisory Authority. The Prospectus, containing full terms and conditions, and application forms are available on the Company’s website, (View Source). The Prospectus will also be available on the Swedish Financial Supervisory Authority’s website, (View Source).

Summary of the Rights Issue

The Rights Issue will, upon full subscription, provide the Company with approximately SEK 236 million before costs related to the rights issue.
Those who on the record date, 24 November 2020, are registered as shareholders of Scandion Oncology will have preferential right to subscribe for new shares in the Rights Issue. For one (1) existing share held on the record date the holder receives one (1) subscription right. Two (2) subscription rights entitle the holder to subscribe for one (1) new share at a subscription price of SEK 22 per share.
The subscription period for subscription of new shares runs from 26 November 2020 up to and including 10 December 2020.
The Rights Issue is covered by approximately 14 per cent subscription undertakings, whereof approximately 4.4 million SEK by insiders. In addition, the Company has received approximately 86 per cent guarantee commitments from external professional investors and is thus fully guaranteed. No compensation is paid for provided subscription undertakings.
Preliminary timetable for the Rights Issue

20 November 2020 Last trading day in Scandion Oncology’s shares including the right to receive subscription rights in the Rights Issue
23 November 2020 First trading day in Scandion Oncology’s shares excluding the right to receive subscription rights in the Rights Issue
24 November 2020 The record date for the Rights Issue
26 November – 10 December 2020 Subscription period of the Rights Issue
26 November – 8 December 2020 Trading in subscription rights on Spotlight Stock Market
26 November – Until conversion of BTAs to new shares Trading in BTAs ongoing until the Danish Business Authority has registered the Rights Issue and BTAs are converted to shares
Around 15 December 2020 The expected date for the announcement of the outcome in the Rights Issue
Around 11 January 2021 Trading in new shares commences

Change of listing to Nasdaq First North Growth Market Sweden

The Board of Directors of Scandion Oncology intends, as a subsequent step following the Rights Issue, to make a list change from Spotlight Stock Market to Nasdaq First North Growth Market Sweden.

Advisors

Vator Securities is financial adviser. and Advokatfirman Schjødt (as to Swedish law) and Plesner Advokatpartnerselskab (as to Danish law) are legal advisers to the Company in connection with the Rights Issue.